DiaMedica reports positive interim results for preeclampsia treatment

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announced positive interim Phase 2 results for DM199 in preeclampsia, demonstrating statistically significant reductions in blood pressure and improved uterine blood flow, with the drug being well-tolerated and not crossing the placental barrier. This development is particularly notable as preeclampsia currently lacks approved pharmacological treatments, positioning DM199 as a potential first-in-class therapy. The company, which reported strong financial health with more cash than debt and a cash runway into Q3 2026, plans to advance DM199 into further study cohorts, while H.C. Wainwright reaffirmed its Buy rating and $10 price target.

Analysis

DiaMedica Therapeutics (DMAC) has reported highly positive interim results from its Phase 2 study of DM199 for preeclampsia, a condition with no approved pharmacological treatments in the U.S. or Europe. The study met its primary safety and efficacy endpoints, demonstrating statistically significant blood pressure reductions that were sustained at 24 hours post-infusion, with the highest dose cohort showing a mean systolic drop of 35 mmHg. Importantly, the trial also indicated a 13.2% improvement in uterine blood flow, and the drug was well-tolerated with only mild adverse events and did not cross the placental barrier. This clinical success is supported by a robust financial position; the company holds more cash than debt, a current ratio of 8.02, and a cash runway projected to last into the third quarter of 2026. Further validation comes from a recent Q1 2025 earnings beat and H.C. Wainwright's reaffirmed Buy rating with a $10 price target, signaling confidence in DM199's potential as a first-in-class therapy. The company will now advance to a dose expansion cohort, with full preliminary results from the current study expected between June and July 2025, representing the next key catalyst.

Key Decisions for Investors

• The positive interim Phase 2 data for DM199 in a market with a significant unmet need positions DiaMedica as a speculative buy for investors with a high-risk tolerance for clinical-stage biotech.
• Investors should note the company's strong financial health, with a cash runway into Q3 2026, which substantially mitigates near-term financing risk and supports the continued development of its pipeline.
• The primary upcoming catalyst to monitor is the release of full preliminary Phase 2 results between June and July 2025, which will be a critical inflection point for the stock's valuation.
• While the reaffirmed $10 price target from H.C. Wainwright provides a bullish benchmark, positions should be managed carefully given the inherent volatility and binary risk associated with clinical trial outcomes for a single-asset-focused company.